Efficacy of Eculizumab in Refractory Life-threatening Warm Autoimmune Hemolytic Anemia Associated with Chronic Myelomonocytic Leukemia

Overview

Journal Clin Case Rep

Date 2020 Dec 28

PMID 33363796

Citations 6

Authors

Anne-Cecile Gauchy

Maxime Hentzien

Alain Wynckel

Victoire de Marcellus

Cyrielle Rodier

Alain Delmer

Anne Quinquenel

Affiliations

Soon will be listed here.

Abstract

Eculizumab may be considered as an emergency therapeutic option in refractory life-threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Citing Articles

Warm autoimmune hemolytic anemia associated with SARS-CoV-2 infection responsive to eculizumab.

Gong Y, Zhang X, Chen X, Yang H, Zhang Y, He G Ann Hematol. 2023; 103(3):1007-1009.

PMID: 38010407 DOI: 10.1007/s00277-023-05549-z.

Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.

Jackson E, Harper S, Webb G, Thomas W BMJ Case Rep. 2022; 15(8).

PMID: 36107725 PMC: 9438040. DOI: 10.1136/bcr-2022-250774.

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies.

Pacillo L, Giardino G, Amodio D, Giancotta C, Rivalta B, Rotulo G Front Immunol. 2022; 13:911385.

PMID: 36052091 PMC: 9426461. DOI: 10.3389/fimmu.2022.911385.

Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.

Migdady Y, Pang Y, Kalsi S, Childs R, Arai S Blood Adv. 2021; 6(8):2707-2721.

PMID: 34972204 PMC: 9043947. DOI: 10.1182/bloodadvances.2021006279.

Autoimmune Complications in Hematologic Neoplasms.

Barcellini W, Giannotta J, Fattizzo B Cancers (Basel). 2021; 13(7).

PMID: 33810369 PMC: 8037071. DOI: 10.3390/cancers13071532.

References

Meulenbroek E, de Haas M, Brouwer C, Folman C, Zeerleder S, Wouters D . Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica. 2015; 100(11):1407-14. PMC: 4825291. DOI: 10.3324/haematol.2015.128991. View

Hadjadj J, Michel M, Chauveheid M, Godeau B, Papo T, Sacre K . Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014; 93(6):521-6. DOI: 10.1111/ejh.12393. View

Fraison J, Mekinian A, Grignano E, Kahn J, Arlet J, Decaux O . Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016; 43:13-7. DOI: 10.1016/j.leukres.2016.02.005. View

Zahid M, Barraco D, Lasho T, Finke C, Ketterling R, Gangat N . Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2016; 58(6):1488-1493. DOI: 10.1080/10428194.2016.1243681. View

Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S . Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012; 87(9):886-9. DOI: 10.1002/ajh.23272. View

Scott L . Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia. Drugs. 2016; 76(8):889-900. DOI: 10.1007/s40265-016-0585-0. View

Benamu E, Montoya J . Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016; 29(4):319-29. DOI: 10.1097/QCO.0000000000000279. View

Wouters D, Zeerleder S . Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Haematologica. 2015; 100(11):1388-95. PMC: 4825292. DOI: 10.3324/haematol.2015.128538. View

Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O . Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leuk Res. 2016; 47:136-41. DOI: 10.1016/j.leukres.2016.05.013. View

10.

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A . Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2014; 14(4):304-13. DOI: 10.1016/j.autrev.2014.11.014. View

11.

Ma K, Caplan S . Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Rep Hematol. 2016; 2016:9181698. PMC: 4820603. DOI: 10.1155/2016/9181698. View

12.

Peker D, Padron E, Bennett J, Zhang X, Horna P, Epling-Burnette P . A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2014; 133(2):249-56. DOI: 10.1159/000365877. View

13.

Roth A, Bommer M, Huttmann A, Herich-Terhurne D, Kuklik N, Rekowski J . Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018; 2(19):2543-2549. PMC: 6177646. DOI: 10.1182/bloodadvances.2018024190. View

14.

Gauchy A, Hentzien M, Wynckel A, de Marcellus V, Rodier C, Delmer A . Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia. Clin Case Rep. 2020; 8(12):2641-2644. PMC: 7752594. DOI: 10.1002/ccr3.3250. View